Tranexamic acid is an active site inhibitor of urokinase plasminogen activator

Law, 2013, New insights into the structure and function of the plasminogen/plasmin system, Curr Opin Struct Biol, 23, 836, 10.1016/j.sbi.2013.10.006

Law, 2012, The x-ray crystal structure of full-length human plasminogen, Cell Reports, 1, 185, 10.1016/j.celrep.2012.02.012

Markus, 1979, The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation, J Biol Chem, 254, 1211, 10.1016/S0021-9258(17)34189-3

Godier, 2017, An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis, 10.1136/jclinpath-2016-203854

Fergusson, 2008, A comparison of aprotinin and lysine analogues in high-risk cardiac surgery, N Engl J Med, 358, 2319, 10.1056/NEJMoa0802395

2011

Morrison, 2012, Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study, Arch Surg, 147, 113, 10.1001/archsurg.2011.287

Roberts, 2014, Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial, Crit Care, 18, 685, 10.1186/s13054-014-0685-8

Gayet-Ageron, 2018, Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients, Lancet, 391, 125, 10.1016/S0140-6736(17)32455-8

Medcalf, 2015, The traumatic side of fibrinolysis, Blood, 125, 2457, 10.1182/blood-2015-02-629808

Hijazi, 2015, Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury

Law, 2017, X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors, Blood Adv, 1, 766, 10.1182/bloodadvances.2016004150

LeBeau, 2013, Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer, Cancer Res, 73, 2070, 10.1158/0008-5472.CAN-12-3526

Holst-Hansen, 1996, Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness, Clin Exp Metastasis, 14, 297, 10.1007/BF00053903

Möbus, 1992, Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines, Int J Cancer, 52, 76, 10.1002/ijc.2910520115

Al-Horani, 2014, Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders, Med Res Rev, 34, 1168, 10.1002/med.21315

Lecker, 2012, Tranexamic acid concentrations associated with human seizures inhibit glycine receptors, J Clin Invest, 122, 4654, 10.1172/JCI63375

Blavignac, 2011, Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment, Semin Thromb Hemost, 37, 713, 10.1055/s-0031-1291382

Longstaff, 2019, Increased urokinase and consumption of α2-antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay, J Thromb Haemost, 10.1111/jth.14338

Silva, 2012, Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator, J Thromb Haemost, 10, 2354, 10.1111/j.1538-7836.2012.04925.x

Mahmood, 2018, Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications, Front Oncol, 8, 24, 10.3389/fonc.2018.00024

Longstaff, 2017, Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH, J Thromb Haemost, 15, 1044, 10.1111/jth.13656

Ooms, 2015, The inositol polyphosphate 5-phosphatase PIPP regulates AKT1-dependent breast cancer growth and metastasis, Cancer Cell, 28, 155, 10.1016/j.ccell.2015.07.003